Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome

The aim of our trial was to evaluate the prognostic significance of qualitative ctDNA analysis on different stages of EGFR mutated non-small cell lung cancer (NSCLC) treatment.We included 99 patients amendable for the first line treatment with either gefitinib/erlotinib (n = 87), afatinib (n = 10) o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: F.V. Moiseenko, N.M. Volkov, A.S. Zhabina, M.L. Stepanova, N.A. Rysev, V.V. Klimenko, A.V. Myslik, E.V. Artemieva, V.V. Egorenkov, N.H. Abduloeva, A.O. Ivantsov, E.S. Kuligina, E.N. Imyanitov, V.M. Moiseyenko
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2022-01-01
coleção:Cancer Treatment and Research Communications
Assuntos:
NSCLC
EGFR
Targeted therapy
ctDNA
Prognosis
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2468294222000132
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados